Skip to content
SEKISUI XenoTech DD Blog Logo

Author: Dr. Maciej Czerwinski

SEKISUI XenoTech Joins Fight Against Liver Disease

SEKISUI XenoTech is committed to furthering the knowledge surrounding hepatic diseases, such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic...

Drug-Drug Interaction (DDI) Prediction Models Following In Vitro Studies in Preclinical Development

In preclinical development, a drug will be evaluated for potential to cause a drug-drug interaction (DDI) using in vitro experiments and then calculations that...

Can Interactions Between Therapeutic Proteins and Small Molecule Drugs Be Evaluated In Vitro?

The mechanisms of clearance for small molecule drugs and therapeutic proteins are fundamentally distinct and therefore therapeutic proteins are generally not...

New Liver Tissue Microarrays Available – What Would Benefit Your Research?

As technology evolves to better meet needs in exploration of drug metabolism pathways and disease mechanisms, familiarization with appropriate and...

New Liver Disease Resource and Other Research Biobank News

SEKISUI XenoTech is committed to furthering the knowledge surrounding hepatic diseases, which affects one out of four people worldwide, such...

Improve the Value of Your Molecule's Testing with Expert Insight

Our expert team of DDI and drug metabolism consultants can help you piece together the data for a successful data package that meets regulatory expectations for thorough risk assessment of a new or repurposed compound

Read our Follow-Up Interview in Outsourcing Pharma

Find the Q&A between Director of Scientific Consulting, Dr. Maciej Czerwinski, and the editorial team at Outsourcing Pharma for more answers about how DDI testing and data interpretation adds value to the drug repurposing process

Human antibodies, including monoclonal and polyclonal, are used for inhibition and immunoblot applications